Cleared Traditional

K080561 - VIDAS CA 125 II ASSAY

K080561 is the FDA 510(k) clearance for VIDAS CA 125 II ASSAY by bioMerieux, Inc.. It is a Class 2 Immunology device (product code LTK) cleared through the Traditional 510(k) pathway after a 407-day FDA review.

K080561 · bioMerieux, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2009
Decision
407d
Days
Class 2
Risk

K080561 is an FDA 510(k) clearance for the VIDAS CA 125 II ASSAY. Classified as Test, Epithelial Ovarian Tumor-associated Antigen (ca125) (product code LTK), Class II - Special Controls.

Submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on April 10, 2009 after a review of 407 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.6010 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Immunology submissions.

View all bioMerieux, Inc. devices

Submission Details

510(k) Number K080561 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 28, 2008
Decision Date April 10, 2009
Days to Decision 407 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
303d slower than avg
Panel avg: 104d · This submission: 407d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LTK Test, Epithelial Ovarian Tumor-associated Antigen (ca125)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.6010
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LTK Test, Epithelial Ovarian Tumor-associated Antigen (ca125)

All 21
Devices cleared under the same product code (LTK) and FDA review panel - the closest regulatory comparables to K080561.
LUMIPULSE G1200 System, LUMIPULSE G CA 125II Immunoreaction Cartridges, LUMIPULSE G CA 125II Calibrators
K142895 · Fujirebio Diagnostics,Inc. · May 2015
DIMENSION VISTA LOCI CA 125 FLEX REAGENT CARTRIDGE,AND DIMENSIONS VISTA LOCI 6 CAL, MODEL#'S K6455, AND KC604
K100321 · Siemens Healthcare Diagnostics · Apr 2011
VIDAS CA 15-3 ASSAY
K080469 · bioMerieux, Inc. · Jun 2009
ARCHITECT CA 125 II ASSAY
K042731 · Fujirebio Diagnostics,Inc. · Nov 2004
ACCESS OV MONITOR ASSAY
K031297 · Beckman Coulter, Inc. · May 2003
ACCESS OV MONITOR IMMUNOENZYMETRIC ASSAY
K023597 · Beckman Coulter, Inc. · Dec 2002